Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized，Double-blind Placebo-controlled Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-stage Small Cell Lung Cancer

NCT04878016 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.

NCT NCT04878016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04878016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized，Double-blind Placebo-controlled Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-stage Small Cell Lung Cancer
Lead sponsor
Lee's Pharmaceutical Limited
Phase
Phase 3
Overall status
Completed
Start date
July 15, 2021
Completion date
October 13, 2023
Enrollment
498 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer